Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234128 | 0.84 | — | — | |
| SCHEMBL18530492 | 0.83 | — | — | |
| SCHEMBL11334971 | 0.81 | GPR35 (0.34) | GPR35 | |
| SCHEMBL16799717 | 0.77 | — | — | |
| SCHEMBL6034426 | 0.74 | — | — | |
| SCHEMBL13998840 | 0.73 | ALDH1A1 (0.33) | — | |
| SCHEMBL17223996 | 0.73 | — | — | |
| SCHEMBL5303478 | 0.73 | — | — | |
| SCHEMBL5389103 | 0.73 | — | — | |
| SCHEMBL5374947 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-1599174-A4 | NOVEL COMPOUNDS | REPLIDYNE INC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070213362-A1 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | REPLIDYNE, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-7220757-B2 | Compositions and methods for topical administration of 2-NH-heteroarylimidazoles | REPLIDYNE, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060287360-A1 | Novel compounds | REPLIDYNE, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060128735-A1 | Substituted thiophenes with antibacterial activity | REPLIDYNE, INC. (US) | 2006-06-15 | — | — | US | disclosed |
| EP-1619947-A4 | ANTIBACTERIAL METHODS AND COMPOSITIONS | REPLIDYNE INC (US) | 2006-05-31 | — | — | EP | disclosed |
| US-7030137-B2 | Substituted thiophenes with antibacterial activity | REPLIDYNE, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1619947-A2 | ANTIBACTERIAL METHODS AND COMPOSITIONS | Replidyne, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20060014748-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | BERGE JOHN | 2006-01-19 | — | — | US | disclosed |
| US-6943175-B2 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| WO-2005009336-A9 | ANTIBACTERIAL METHODS AND COMPOSITIONS | REPLIDYNE INC (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005009336-A2 | ANTIBACTERIAL METHODS AND COMPOSITIONS | REPLIDYNE, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050009833-A1 | Substituted thiophenes with antibacterial activity | REPLIDYNE, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040224981-A1 | Antibacterial methods and compositions | REPLIDYNE, INC. | 2004-11-11 | — | — | US | disclosed |
| WO-2004078119-A2 | SUBSTITUTED THIOPHENES WITH ANTIBACTERIAL ACTIVITY | REPLIDYNE INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004069196-A2 | NOVEL COMPOUNDS | REPLIDYNE, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040147548-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004052288-A2 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | REPLIDYNE, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2000071524-A1 | 2-NH-PYRIDONES AND PYRIMIDONES AS MRS INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147548-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | NSUN3, TRMT1, NOP2 | GPR35 4034/4885 |
| US-20060287360-A1 | Novel compounds | NSUN3, RNGTT, EMG1 | GPR35 3666/4885 |
| US-20040224981-A1 | Antibacterial methods and compositions | AARS1, NOP2, NSUN3 | GPR35 4489/4885 |
| US-20050009833-A1 | Substituted thiophenes with antibacterial activity | TST, MTR, NSUN3 | GPR35 3555/4885 |
| US-20060128735-A1 | Substituted thiophenes with antibacterial activity | TST, MTR, NSUN3 | GPR35 3555/4885 |
| US-20070213362-A1 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | MET, ASNS, MRPS22 | GPR35 2648/4885 |
| US-20060014748-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | TRMT1, NSUN3, NOP2 | GPR35 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.